Sanofi's MS Drug Tolebrutinib receives a positive review and recommendation from CHMP for EU approval, despite its rejection in the US. The company's financial position is strong, with posted higher sales and robust Q1 2026 earnings, backed notably by Dupixent. This growth occurred amidst a leadership transition with the arrival of a new CEO, intending to implement a novel growth strategy. Nevertheless, the company has experienced several setbacks in Research and Development. Beyond Dupixent, Sanofi secures approval for Tzield in pediatric diabetes, indicating progress in its research portfolio. Despite some market skeptism of longer-term growth prospects, Sanofi maintains its 2026 outlook. However, mixed responses on the company's performance abound in the analyst circles.
Sanofi News Analytics from Thu, 20 Nov 2025 08:00:00 GMT to Sat, 25 Apr 2026 10:00:00 GMT -
Rating 6
- Innovation 4
- Information 6
- Rumor -6
